Previous studies have demonstrated that modulation of the endocannabinoid system by selective inhibitors of the endocannabinoids’ catabolic enzymes—FAAH and MAGL—may represent a new therapeutic strategy for migraine [26,27,28,29,30]. The gene discussed is FAAH; the disease is migraine disorder.